Abstract 295P
Background
During the last two decades, health-related quality of life (QoL) measurements have been an important issue in understanding the difficulties perceived in many diseases. It is important to assess the health-related quality of life to know the extent of diseases and conditions affecting individual’s general well-being. Studies have shown the effect various determinants of Quality of Life (QoL) in lung cancer patients. This study was done to assess the QoL in individuals with non- small cell lung cancer undergoing palliative care.
Methods
Materials and Method: Data on QoL were collected using a modified MOS-SF form-32. The study was done in 27 individuals before and after providing supportive or palliative care. A random mixed linear model was used to assess impact of palliative care on Quality of Life with Physical Health Summary score and Mental Health Summary score as main outcomes. All the possible confounding factors were controlled in the study.
Results
When values were compared before and after giving palliative care the Physical Health Summary score decreased considerably. (diff=-2.12; 95% CI: [-4.08, -0.63]) with small to medium effect sizes. The PHS Score remained lower after being on palliative care for more than 2 years (diff=-5.86; 95% CI: [-7.89, -3.63]).]). The Mental Health summary score didn’t change significantly after giving palliative care (diff=-5.86; 95% CI: [-7.89, -3.63]). The Mental Health summary score was higher after HAART for more than 5 years when compared prior to infection.
Conclusions
Quality of life is an important determinant in the course of lung cancer. Palliative or supportive care can play a vital role in improving the quality of life in patients with lung cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
104P - Safety and efficacy of HLX04 versus reference bevacizumab in combination with XELOX or mFOLFOX6 as first-line treatment for metastatic colorectal cancer: A randomised, double-blind phase III study
Presenter: Shukui Qin
Session: e-Poster Display Session
105P - Prospective, open-label, observational study of cetuximab for metastatic colorectal carcinoma (mCRC): The OPTIM1SE study
Presenter: Tsai-Sheng Yang
Session: e-Poster Display Session
106P - Efficacy and tolerability of capecitabine and mitomycin-C based concurrent radiotherapy in patients with anal canal cancer
Presenter: Prabhat Bhargava
Session: e-Poster Display Session
107P - Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in previously treated metastatic colorectal cancer (mCRC): Results from the Australian cohort of the phase IIIb, international, open-label, early-access PRECONNECT study
Presenter: Timothy Price
Session: e-Poster Display Session
108P - Comparative analysis of two-stage hepatectomy and enhanced one-stage hepatectomy in the setting of bilobar colorectal liver metastases
Presenter: Hayk Torgomyan
Session: e-Poster Display Session
109P - Efficacy and safety of biweekly or triweekly XELOX regimen for adjuvant chemotherapy of colorectal cancer
Presenter: hangyu zhang
Session: e-Poster Display Session
110P - Analysis for stereotactic body radiotherapy (SBRT) effect for colorectal liver metastases
Presenter: Wei Zou
Session: e-Poster Display Session
111P - A meta-analysis study on safety and effectiveness comparison between FOLFOX and XELOX regiments on advanced stage colorectal cancer
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
112P - Pembrolizumab vs chemotherapy in patients with microsatellite instability-high/mismatch repair deficient metastatic colorectal cancer: Asia subgroup results of the phase III KEYNOTE-177 study
Presenter: Takayuki Yoshino
Session: e-Poster Display Session
122P - Nomogram to predict short-term effect of radiotherapy based on pre/post-treatment inflammatory biomarkers and their dynamic changes in esophageal squamous cell carcinoma
Presenter: Shuai Liang
Session: e-Poster Display Session